Search Results
53 Results Found for “circulating tumour DNA”
The 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona brought together over 9,400 participants, marking a major milestone. The meeting highlighted major advances in oncologic imaging and theranostics, with a strong emphasis on precision medicine and combination treatment strategies. Across plenary sessions, debates, and late-breaking discussions, the meeting underscored how nuclear medicine is increasingly central to cancer diagnosis, treatment selection, and therapeutic delivery.
In this Future Leaders interview, Dr Kevin Keane discusses the mentors who shaped his approach to clinically meaningful research, the integration of surgery and innovation in uro-oncology and the collaborative, patient-centred advances set to transform bladder cancer care.
The 15th European Breast Cancer Conference (EBCC15) showcased a wave of research poised to reshape breast cancer care. Below, we spotlight the key highlights from this year’s conference.
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, comprising approximately 85% of all primary liver cancers.1Â Globally, it ranks as the sixth-most common cancer and the third-leading cause of cancer-related mortality, with over 900,000 new cases and 830,000 deaths ...
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
At #ASCO25, Dr Frank Sinicrope discussed major colon cancer trial updates, including ctDNA’s prognostic power post-surgery, the limitations of chemotherapy escalation in high-risk patients, and survival gains with first-line encorafenib + cetuximab + mFOLFOX6 in BRAF-mutant mCRC. These findings may reshape risk stratification and frontline treatment strategies.
Dr Satish Nadig describes Northwestern Medicine’s first use of the RAPID procedure to treat metastatic colorectal cancer with liver transplantation. He outlines the innovative surgical techniques, the promise of the CLEAR program, and the future potential of machine perfusion technology to extend transplant opportunities to more patients.
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
We’re thrilled to welcome Dr. Ken Kato (National Cancer Center Hospital, Tokyo, Japan) to discuss the unique advantages and challenges of conducting cancer research in Japan. Key advantages include robust regulatory support, streamlined trial approvals and strong collaboration with ...
Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (...
Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has ...
Cholangiocarcinoma (CCA) is a cancer of the epithelial cells lining the biliary tree in the liver and can occur both inside the liver (intrahepatic CCA [iCCA]) and outside the liver (extrahepatic CCA, which includes both perihilar and distal cholangiocarcinoma) (Figure 1). ...
The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. ...
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
